Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
immunoBON in allergic rhinoconjunctivitis
DRKS00032757Phase 4Completed
- Sponsor
- Bencard Allergie
- Start
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of immunoBON in allergic rhinoconjunctivitis (ARC), asthma, cat allergy and 2 more, sponsored by Bencard Allergie. Started Sep 2023; status: completed.
02
Drugs
immunoBON
03
Conditions
allergic rhinoconjunctivitis (ARC)asthmacat allergyhouse dust mite allergyseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on DRKS00032757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00032757.